The HNF-4 orphan receptor is a member of the nuclear receptor family of transcription factors and a major regulator of genes involved in carbohydrate and lipid metabolism. As an initial step in characterizing the role of HNF-4 in the regulation of metabolism, we have generated a 
INTRODUCTION
The HNF-4 orphan receptor is a member of the zinc-finger nuclear receptor superfamily of transcription factors (1) . Three isoforms of HNF-4 exist: HNF-4α1 (1-4), HNF-4α2 a splice variant containing a 10 amino acid insert (3, 4) and HNF-4α3 which has a 1-2 kDa larger N-terminus (5) . Whereas, HNF-4 is active as a homodimer (1, 6) , most other members of the nuclear receptor superfamily form transcriptionally-active heterodimers (7) (8) (9) (10) (11) (12) . HNF-4 regulates transcription of a variety of genes involved in carbohydrate (5, (13) (14) (15) (16) (17) and lipid (5, 13, (18) (19) (20) (21) metabolism. Either alone or in concert with other transcription factors, HNF-4 also regulates the expression of a variety of apolipoprotein genes, including apo CIII (22) (23) (24) , apo AI (25) (26) (27) (28) , apo A-IV (29, 30) , apo B (24, 31) and apo AII (24) . Moreover, disruption of the HNF-4 gene by homologous recombination was lethal to homozygous mouse embryos, with gross structural abnormalities occurring very early in development (32) . Taken together, these observations suggest that HNF-4 plays an important role in the regulation of energy metabolism and in development.
Dominant negative mutant forms of steroid receptors have been constructed by mutating the ligand binding (33) , DNA binding (33) or transactivation (34) domains. The zinc-finger DNA-binding domain of HNF-4 contains the invariant cysteine residues typifying this family of nuclear receptors (1, 7) . In the human glucocorticoid receptor, point mutations of any one of these cysteine residues abolished DNA binding and transactivation (35) . By mutating one of the zinc-finger cysteine residues in human HNF-4, we have generated a dominant-negative form of the protein, termed DN-HNF-4, that specifically inhibits HNF-4-dependent transcription. In the current study, we describe this mutation, and characterize its effect on the binding of HNF-4 to DNA and on transcriptional activity of an HNF-4-dependent promoter. Our results indicate that DN-HNF-4 is an effective and specific inhibitor of wild-type HNF-4, and should provide a very useful tool for the study of HNF-4 in the regulation of energy metabolism.
MATERIALS AND METHODS

Plasmid constructions
PCR primers derived from the published sequence of rat HNF-4 (1) were used to generate cDNA clones encoding the HNF-4α1 and HNF-4α2 isoforms from a human fetal liver cDNA library (Clonetech). A number of HNF-4 mutant cDNA clones were generated by PCR using low stringency conditions. In one of the resulting mutants, thymine at postion 316 was replaced by cytosine in HNF-4α2. This nucleotide change resulted in a mutated form of HNF-4α2 protein, termed DN-HNF-4, in which the cysteine residue at amino acid 106 was replaced by an arginine (Fig. 1) . The PCR products were cloned into the pCRII vector (Invitrogen) and then transferred into the mammalian expression vector, pcDNA3 (Invitrogen). To maximize expression, a Kozak sequence (GGCACC) (36) was incorporated immediately upstream of the initiation site. Mouse RXRα and mouse PPARγ expression vectors were obtained from S. Tafuri and B. O'Malley respectively. The wild-type apo CIII construction, pL854 consists of a KpnI-HindIII fragment containing the human apo CIII promoter sequence from -854 to +22 inserted upstream of the luciferase gene in the pGL2-Basic vector. pL854a.1 is identical to pL854 except that a 5 nt fragment was removed between -84 and -78, and replaced with an 8 nt XhoI linker fragment (22) . pL854a.2 is identical to pL854 except for a single base pair mutation at -77 that was incorporated by site-directed mutagenesis (37) .
Transfection
HepG2 cells were maintained in MEM supplemented with 10% fetal bovine serum and penicillin-streptomycin. In addition to selected amounts of HNF-4 isoforms and DN-HNF-4, each transfection contained 1 µg apo CIII-luciferase reporter plasmid, 0.1 µg β-galactosidase expression vector pSV-β-GalactosidaseControl (Promega) as an internal reference, and sufficient amount of empty pcDNA3 vector to raise the total quantity of transfected DNA to 2.5 µg per 22 mm cell culture well. Following a 4 h transfection period, the cells were incubated in MEM plus 10% fetal bovine serum for an additional 36 h. Following cell lysis, chemiluminescence assays were utilized for quantitating luciferase (Promega) and β-galactosidase (Tropix). Luciferase activity was normalized by β-galactosidase activity to account for transfection efficiency.
In vitro translation and gel mobility shift assay
Recombinant HNF-4 proteins were synthesized in a reticulocyte lysate based transcription-translation system using T7 RNA polymerase (Promega). [ 35 S]Methionine labeling revealed the proteins were synthesized efficiently at the expected molecular weight (data not shown). Double-stranded oligonucleotide probes containing the wild-type human apo CIII HNF-4 binding site sequence (-92 to -61) 5′-GGGTCAGCAGGTGACCTTTGCC-CAGCGCCCTGG-3′ and the rat acyl-CoA PPAR binding site (-574 to -553) 5′-GGGTCAGCACGTGACCTTTGTCCTGC- GCCCTGG-3′ were radiolabeled with [γ-32 P]dCTP using Klenow fragment. Corresponding non-radiolabeled probes were used as competitor oligonucleotides. The NF-κB competitor oligonucleotide was obtained from Oncogene Sciences.
DNA binding reactions were performed in 20 µl containing: 20 mM HEPES pH 7.9, 60 mM KCl, 3% Ficoll, 1 mM MgCl 2 , 0.03% Nonidet P-40, 1.0 mM DTT, 50 ng poly(dI-dC), and 20 000 c.p.m. of radiolabeled probe. In vitro translated proteins were preincubated at room temperature for 45 min, to allow protein dimerization, and for an additional 15 min with the DNA probe. A constant amount of reticulocyte lysate was maintained by adding lysate containing the translated proteins from an empty pcDNA3 vector. The DNA-protein complexes were analyzed on 6% polyacrylamide gels (Novex) using 0.5× TBE running buffer. The gels were dried, analyzed quantitatively using a PhosphorImager (Molecular Diagnostics), and an autoradiogram obtained by film exposure at -70_C. HepG2 cell (38) and mouse liver nuclear (39) extracts were prepared according to methods previously reported.
RESULTS
Based on previous findings (35), we expected that a mutation in one of the zinc-finger domains of HNF-4 would generate a protein that was incapable of binding DNA, but was still capable of forming homodimers. Such a protein would form non-functional heterodimers with wild-type HNF-4, thereby blocking much of the cellular HNF-4 activity. A point mutation was introduced into a cDNA clone of the α2 isoform of the human HNF-4 gene (Fig. 1A) . This change converted the cysteine at position 106 to an arginine (Fig. 1B) , thereby disrupting the zinc coordination complex. This mutated HNF-4α2 protein was termed DN-HNF-4.
Recombinant forms of both α1 and α2 wild-type proteins also were produced to determine if DN-HNF-4 was capable of inhibiting HNF-4 binding activity. Both isoforms of wild-type HNF-4 specifically bound an oligonucleotide probe representing the HNF-4 binding site element (C3P) from the human apo CIII promoter ( Fig. 2A, lanes 5 and 6) . DN-HNF-4 was incapable of binding the C3P probe (Fig. 2A, lane 1) . The binding of HNF-4α1 and HNF-4α2 to the C3P probe was inhibited by increasing amounts of in vitro synthesized DN-HNF-4 ( Fig. 2B and C) . The highest amount of DN-HNF-4 inhibited the binding of HNF-4α1 by 71% and HNF-4α2 by 84%. DN-HNF-4 nearly abolished C3P binding activity produced by nuclear extracts from HepG2 cells (Fig. 2D, lanes 1 and 2) and mouse liver (Fig. 2D, lanes 4 and 5) . It is known that C3P binds other nuclear receptor superfamily members, such as apolipoprotein A1 regulatory protein (ARP-1) and Ear3/COUP-TF (23) . However, in agreement with our observations the majority of C3P binding activity from HepG2 cell and liver cell nuclear extracts is believed to be contributed by HNF-4 (1,22,23). Interestingly, C3P bound protein from HepG2 cells appeared to be larger and less diffuse than that observed for mouse liver nuclear extracts. The distinct binding patterns could be due to differential expression and gel mobility differences of the homo-or heterodimers formed by HNF-4α1, α2 and α3, or the recently described HNF-4α4 or HNF-4γ proteins (40) .
To obtain an indication of specificity, we examined the ability of DN-HNF-4 to disrupt the DNA binding of two other nuclear receptors, PPARγ and RXRα. DN-HNF-4 did not interfere with RXRα-PPARγ heterodimer binding to a probe representing the PPAR response element (PPRE) in the acyl-CoA oxidase promoter (Fig. 2E, lane 4) . Thus, DN-HNF-4 does not hinder the heterodimerization and DNA binding of two other important nuclear receptors. Taken together, these results indicate that DN-HNF-4 is a specific dominant negative protein that forms defective dimeric complexes with HNF-4α1, HNF-4α2 and endogenous wild-type HNF-4 that are incapable of DNA binding.
The effect of DN-HNF-4 on the transcriptional activity of HNF-4 in vivo was examined by using the human apo CIII gene promoter which contains the essential HNF-4 binding site, C3P (Fig. 3) (1,22-24 ). Increasing amounts of plasmids encoding DN-HNF-4 caused a dose-dependent reduction of constitutive apoCIII transcriptional activity (Fig. 4) . In contrast, cotransfection of plasmids expressing either wild-type HNF-4α1 or HNF-4α2 isoforms markedly increased transcriptional activity of the apo CIII promoter (Fig. 4) . To confirm the effects of cotransfected HNF-4 proteins were dependent on the C3P site, we examined the transcriptional activity of apo CIII promoter constructs containing two different C3P site mutations (Fig. 3) . Previous results have shown that apo CIII promoter transcriptional activity was attenuated by the single base-pair mutation in C3P of pL854a.2 (37) and nearly abolished by the 5 bp disruption in C3P of pL854a.1 (22) . When the recombinant HNF-4 receptor isoforms were cotransfected with the mutated apo CIII promoters, the positive transcriptional responses were partially attenuated in pL854a.2 and dramatically reduced in pL854a.1 ( Fig. 5A and B) . Cotransfection of DN-HNF-4 produced dose-dependent decreases in transcriptional activity of the mutated apo CIII promoter constructs (Fig. 5C ). Maximal transcriptional repression was most pronounced for the wild-type apo CIII promoter, pL854 (17.9-fold repression), less for the single base-pair changed promoter, pL854a.2 (4.4-fold repression) and least for the 5 bp mutated promoter, pL854a.1 (2.2-fold repression) (Fig. 5D) . Therefore, in vivo the ability of DN-HNF-4 to repress apo CIII promoter transcriptional activity is dependent on the presence of the C3P regulatory element.
To ascertain if there was a preferential blockade of either isoform, DN-HNF-4 was cotransfected with plasmids expressing either HNF-4α1 or HNF-4α2. Wild-type apo CIII promoter activity was elevated incrementally by both receptor isoforms ( Fig. 6A and B) . DN-HNF-4 reduced dose-dependently the transcriptional responses evoked by HNF-4α1 (Fig. 6A) and HNF-4α2 (Fig. 6B) . There was no remarkable difference in the (1), as well as with a study showing that a single point mutation in the second zinc finger of the human glucocorticoid receptor abolishes DNA binding activity (35) . In addition, a dominant negative mechanism of this nature has been reported for the retinoic acid receptor (33) and may occur naturally with the c-erbAα2 variant in the thyroid hormone family of receptors (41) .
A number of observations indicate the in vivo effects of DN-HNF-4 were the result of selective inhibition of HNF-4 and were not due to a general, non-specific repression of transcription. First, DN-HNF-4 did not reduce the expression of the reference β-galactosidase expression plasmid which is driven by the CMV promoter. Second, the transcriptional activity of the mutated apo CIII promoter construct, although low in comparison with the wild-type apo CIII promoter, was not reduced further by amounts of transfected DN-HNF-4 expression plasmid capable of nearly abolishing wild-type promoter activity. Third, in gel mobility shift experiments DN-HNF-4 failed to affect the binding of PPARγ-RXRα heterodimers to a probe representing a PPAR response element. Finally, unlike many other nuclear receptors, HNF-4 forms functional homodimers and does not appear to dimerize with other family members (1, 6) .
A major portion of the constitutive activity of the apo CIII promoter in HepG2 cells is believed to be contributed by HNF-4, since mutation of the C3P element dramatically reduced apo CIII transcriptional activity in these cells (22, 37) . Our results using DN-HNF-4 support this role for HNF-4 in apo CIII transcription. For the wild-type apo CIII promoter, a residual transcriptional activity of only 5% of control remained after the highest dose of DN-HNF-4 suggesting that 95% of basal apo CIII transcriptional activity is due to HNF-4. This residual activity could be due to HNF-4 dimers that were not blocked by DN-HNF-4 or to the presence of other transcription factors known to bind the apo CIII promoter [e.g., CIIIB1 (42), NF-BA1 (43)].
DN-HNF-4 produced dose-dependent inhibition of HNF-4α1 and HNF-4α2 induced apo CIII promoter transcriptional activity. Most dramatic inhibition was produced when the ratio of transfected DN-HNF-4 was at least 80-fold greater than either HNF-4 isoform. The necessity for a large excess of DN-HNF-4 is unknown, but could be due to a reduced synthesis or increased degradation of DN-HNF-4 compared with wild-type HNF-4. Also, since the dimerization domain of DN-HNF-4 is not affected by the zinc-finger mutation, it is likely that DN-HNF-4 dimerizes with itself as well as with wild-type HNF-4; thereby reducing the effective concentration of DN-HNF-4. Lastly, wild-type HNF-4 bound to DNA may not be available for dimerization with DN-HNF-4.
Dimerization between nuclear receptor isoforms is not uncommon (44) (45) (46) (47) . It has not been determined whether HNF-4α1 and HNF-4α2 form transcriptionally-active heterodimers. Since, our results demonstrate that DN-HNF-4 binds both HNF-4α1 and HNF-4α2, it is reasonable to conclude that wild-type HNF-4 receptor subtypes do form dimers with each other. The role the different HNF-4 isoform heterodimers play in gene transcription remains to be determined.
We conclude from these studies that DN-HNF-4 is an effective dominant negative mutant that selectively inhibits HNF-4-mediated transcriptional activity. The mechanism of action involves the formation of inactive DN-HNF-4/HNF-4 dimers that are not capable of binding the HNF-4 response element. It is anticipated that DN-HNF-4 will be useful in exploring the role that HNF-4 plays in regulating transcription.
